For instance, a meta-analysis confirmed that a high pretreatment NLR was predictive of reduced OS and progression-free survival (PFS) in advanced NSCLC patients treated with PD-1/PD-L1 inhibitors (8). The gene discussed is CD274; the disease is non-small cell lung carcinoma.